Celgene (NASDAQ: CELG) has recently received a number of price target changes and ratings updates:

  • 12/14/2017 – Celgene was given a new $166.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/13/2017 – Celgene had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $120.00 price target on the stock.
  • 12/12/2017 – Celgene was given a new $128.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 12/12/2017 – Celgene was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $121.72 price target on the stock.
  • 12/12/2017 – Celgene is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $114.00 price target on the stock.
  • 12/12/2017 – Celgene was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/11/2017 – Celgene was given a new $112.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 12/10/2017 – Celgene had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 12/8/2017 – Celgene was upgraded by analysts at Atlantic Securities from a “neutral” rating to an “overweight” rating.
  • 11/22/2017 – Celgene had its “buy” rating reaffirmed by analysts at Cann. They now have a $166.00 price target on the stock. They wrote, “We conducted a physician survey to evaluate the current treatment preferences and satisfaction with available therapies, along with expectations for therapies in clinical development. Our report (published 11/21/17), Multiple Sclerosis Survey: Unmet Need Persists Despite Several Approved Treatment Options, concluded that there is a meaningful unmet need in MS treatment and a high level of interest in Ozanimod if FDA-approved. We conclude that approximately 80% of the neurologists surveyed are unsatisfied with the therapies available to them. The survey showed that 40.4% of patients are being treated with oral therapy. The surveyed neurologists replied that they would, on average, put 23.8% of their patients on a newly approved therapy they had selected from the survey.””
  • 11/17/2017 – Celgene was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 11/17/2017 – Celgene had its price target raised by analysts at BMO Capital Markets from $148.00 to $155.00. They now have an “outperform” rating on the stock.
  • 11/16/2017 – Celgene was given a new $140.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/16/2017 – Celgene was given a new $166.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/3/2017 – Celgene had its “buy” rating reaffirmed by analysts at Mizuho.
  • 10/30/2017 – Celgene had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $166.00 price target on the stock, up previously from $163.00.
  • 10/30/2017 – Celgene had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $112.00 price target on the stock. They wrote, “SUNBEAM and RADIANCE Shine Bright. Both these studies (one year and two years, respectively), in our view, show ozanimod to be a competitive agent in the field, with statistically significant reductions in annualized relapse rate for both time intervals: 48% at one year and 38% at two years for the 1 mg dose.””
  • 10/27/2017 – Celgene was given a new $123.00 price target on by analysts at J P Morgan Chase & Co. They now have a “buy” rating on the stock.
  • 10/27/2017 – Celgene had its price target lowered by analysts at UBS AG from $146.00 to $120.00. They now have a “buy” rating on the stock.
  • 10/27/2017 – Celgene had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $140.00 price target on the stock, down previously from $154.00.
  • 10/27/2017 – Celgene had its price target lowered by analysts at BMO Capital Markets from $163.00 to $148.00. They now have an “outperform” rating on the stock.
  • 10/27/2017 – Celgene had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $105.00 price target on the stock, down previously from $135.00.
  • 10/27/2017 – Celgene had its price target lowered by analysts at Citigroup Inc. from $140.00 to $102.00. They now have a “neutral” rating on the stock.
  • 10/27/2017 – Celgene had its price target lowered by analysts at SunTrust Banks, Inc. from $156.00 to $127.00. They now have a “buy” rating on the stock.
  • 10/27/2017 – Celgene had its price target lowered by analysts at Royal Bank of Canada from $166.00 to $148.00. They now have a “top pick” rating on the stock.
  • 10/27/2017 – Celgene was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating.
  • 10/27/2017 – Celgene had its “sell” rating reaffirmed by analysts at Goldman Sachs Group Inc. They now have a $91.00 price target on the stock, down previously from $116.00.
  • 10/27/2017 – Celgene was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating.
  • 10/27/2017 – Celgene was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating.
  • 10/27/2017 – Celgene had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $103.00 price target on the stock.
  • 10/26/2017 – Celgene had its “buy” rating reaffirmed by analysts at Cann.
  • 10/26/2017 – Celgene was downgraded by analysts at UBS AG from a “strong-buy” rating to a “market perform” rating. They now have a $160.00 price target on the stock.
  • 10/26/2017 – Celgene was downgraded by analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating.
  • 10/26/2017 – Celgene was given a new $162.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/23/2017 – Celgene is now covered by analysts at Guggenheim. They set a “buy” rating and a $160.00 price target on the stock.
  • 10/23/2017 – Celgene had its price target lowered by analysts at Morgan Stanley from $120.00 to $115.00. They now have an “underweight” rating on the stock.
  • 10/23/2017 – Celgene had its “neutral” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $133.00 price target on the stock.
  • 10/23/2017 – Celgene was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $144.39 price target on the stock.
  • 10/22/2017 – Celgene had its “hold” rating reaffirmed by analysts at BTIG Research. They wrote, “After mkt-close on Thursday, Celgene announced termination of the Phase 3 studies (REVOLVE and SUSTAIN) for mongersen in the treatment of Crohn’s disease, and that the Phase 3 DEFINE study will not be initiated. Termination of the programs follow the recommendation of the Data Monitoring Committee (DMC) who indicated futility of mongersen in producing a clinical benefit. Based on the announcement, we have taken our 2023 mongersen estimates to zero from $215m previously, versus consensus at ~$1bn.””
  • 10/20/2017 – Celgene had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $156.00 price target on the stock.
  • 10/20/2017 – Celgene had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $170.00 price target on the stock.
  • 10/20/2017 – Celgene had its “buy” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $163.00 price target on the stock.
  • 10/20/2017 – Celgene had its price target lowered by analysts at Barclays PLC from $135.00 to $105.00. They now have an “equal weight” rating on the stock.
  • 10/20/2017 – Celgene had its “outperform” rating reaffirmed by analysts at William Blair.
  • 10/20/2017 – Celgene had its price target lowered by analysts at UBS AG from $153.00 to $146.00. They now have a “buy” rating on the stock.
  • 10/20/2017 – Celgene had its price target lowered by analysts at Stifel Nicolaus from $155.00 to $149.00. They now have a “buy” rating on the stock.
  • 10/20/2017 – Celgene was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating.
  • 10/20/2017 – Celgene was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $136.00 price target on the stock, down previously from $162.00.
  • 10/18/2017 – Celgene was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. Moreover, shares of Celgene have outperformed the industry in the year so far. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure.”
  • 10/17/2017 – Celgene is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $162.00 price target on the stock.
  • 10/17/2017 – Celgene had its price target raised by analysts at BMO Capital Markets from $160.00 to $167.00. They now have a “positive” rating on the stock.
  • 10/16/2017 – Celgene had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/16/2017 – Celgene had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $160.00 price target on the stock.
  • 10/16/2017 – Celgene was given a new $162.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.

Shares of Celgene Co. (CELG) opened at $108.24 on Friday. The firm has a market cap of $85,849.04, a P/E ratio of 17.04, a price-to-earnings-growth ratio of 0.84 and a beta of 1.78. Celgene Co. has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. equities research analysts anticipate that Celgene Co. will post 6.67 EPS for the current year.

In other news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.95% of the company’s stock.

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Ratings for Celgene Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co and related companies with MarketBeat.com's FREE daily email newsletter.